---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-027860"
form_type: "8-K"
ticker: "IDXG"
cik: "0001054102"
company_name: "INTERPACE BIOSCIENCES, INC."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:42:19.490062+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Interpace Q3 revenue $9.5M, net loss $3.6M; new $7.5M facility, $8M term loan, $30M rights offering

## Summary
- Q3 revenue $9.5M (+15% YoY); loss from continuing ops $(3.5)M vs $(6.2)M; adjusted EBITDA $(1.8)M vs $(2.9)M.
- Cash collections $10.4M (2nd consecutive record quarter); DSO down 48% YoY to 59 days; cash $3.2M at Sep 30.
- Entered $7.5M Comerica revolver (matures Sep 2023) and $8M BroadOak term loan to repay private equity bridge loans.
- Proposed $30M rights offering (backstopped by 3K Limited Partnership) to fund growth; goal $100M revenue run rate by 2023.
- Expanded payor contracts: 54 commercial payors for thyroid tests; two new patents granted for ThyraMIR and PancraGEN technologies.

## SEC filing metadata
- accession: 0001493152-21-027860
- form_type: 8-K
- ticker: IDXG
- cik: 0001054102
- company_name: INTERPACE BIOSCIENCES, INC.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1054102/000149315221027860/0001493152-21-027860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1054102/000149315221027860/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-027860
- JSON: https://secwatch.observer/filing/0001493152-21-027860.json
- Plain text: https://secwatch.observer/filing/0001493152-21-027860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.